Scripps Research Logo

The Gallay Laboratory


2016 | 20152014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003


Chatterji U, Bobardt M, Schaffer L, Wood M, Gallay PA. 2016. Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection. PLoS One. 11(7):e0159511.

Gallay PA,Chatterji U, Bobardt MD, Long Z, Zhang S, Su Z. 2016. Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175. PLoS One. 11(4):e0152036.


Chatterji U, Bobardt M, Tai A, Wood M, & Gallay PA. 2015. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. Antimicrob Agents Chemother. 59(5):2496-2507.

Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, & Foster R. 2015. The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action. PLoS One. 10(8): e0134707.

Hansson MJ, Moss SJ, Bobardt M, Chatterji U, Coates N, Garcia-Rivera JA, Elmer E, Kendrew S, Leyssen P, Neyts J, Nur EAM, Warneck T, Wilkinson B, Gallay P, & Gregory MA. 2015. Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection. Chem Biol. 22(2):285-292.

Hopkins S, & Gallay PA. 2015. The role of immunophilins in viral infection. Biochim Biophys Acta. 1850(10):2103-2110.

Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R, Gallay P, & Naoumov NV. 2015. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production. Gastroenterology. 148(2):403-414.e407.

Veazey RS, Chatterji U, Bobardt M, Russell-Lodrigue KE, Li J, Wang X, & Gallay PA. 2015. C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge. Antimicrob Agents Chemother. 60(1):693-698.


Lim PJ, Gallay PA. 2014. Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol. 8C:30-37.

Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W, Brass CA, Naoumov NV, Gallay PA. 2014. The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance. Antimicrob Agents Chemother. 58(6):3327-3334.

Gawlik K, Gallay PA. 2014. HCV core protein and virus assembly: what we know without structures. Immunol Res. 60(1):1-10.

Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD, Gallay PA. 2014. HCV core residues critical for infectivity are also involved in core-NS5A complex formation. PLoS One. 9(2):e88866.

Gallay P. 2014. Resistance to Cyclophilin Inhibitors. In M. Gotte, A. Berghuis, G. Matlashewski, M. Wainberg, & D. Sheppard (Eds.), Handbook of Antimircrobial Resistance: 1-24.

Chamoun-Emanuelli AM, Bobardt M, Moncla B, Mankowski MK, Ptak RG, Gallay P, & Chen Z. 2014. Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide. Antimircrob Agents Chemother. 58(2): 687-697.

Bobardt M, Chatteriji U, Lim P, Gawlik K, & Gallay P. 2014. Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activaion in HCV-Infected Cells. Open Virol J. 8:1-8.


Baugh JM, Garcia-Rivera JA, Gallay PA. 2013. Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res. 100(2):555-561.

Gallay PA, Ptak RG, Bobardt MD, Dumont JM, Vuagniaux G, Rosenwirth B. 2013. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses. 5(3):981-97.

Gallay PA, Lin K. 2013. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther. 7:105-115.


Hopkins, S., DiMassimo, B, Rusnak, P., Heuman, D., Lalezari, J., Sluder, A., Scorneaux, B., Mosier, S., Kowalczyk, P., Ribeill, Y., Baugh, J., and Gallay, P.A. 2012. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol. 56(7):3888-3897.

Maskiewicz, R., Bobardt, M., Chatterji, U., Gunaseelan, S., Dezzutti, C.S., Penin, F., and Gallay, P.A. 2012. Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities. Antimicrobial Agents and Chemotherapy. 56(6):3336-3343.

Selvarajah, S. Chatterji, U., Kuhn, R., Kinney, Vasudevan, S. G., and Gallay, P.A. 2012. Development and evaluation of an enzyme-linked immunosorbent assay for Dengue capsid. The Open Virology Journal. 6:29-37.


Gallay, P.A. 2011. Cyclophilin inhibitors: a novel class of promising host targeting anti-HCV agents. Immunologic Research. 13(3):403-417.

de Witte, L., Bobardt, M.D, Chatterji, U., van Loenen, F.B., Verjans, G.M., Geijtenbeek, T.B.H. and Gallay, P.A. 2011. HSV Neutralization by the Microbicidal Candidate C5A. PLoS One, 6(5):e18917.

Gregory, M.A., Moss, S. J., Coates, N., Foster, T., Bobardt, M., Chatterji, U., Gallay, P. A., Leyssen, P., Neyts, J., Nur-E-Alam, M., Piraee, M., Suthar, D., Warneck, T., Zhang, M.-Q., and Wilkinson, B. 2011. Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. Antimicrobial Agents and Chemotherapy, 55:1975-1981.

Foster, T., Gallay, P.A., Stonehouse, N. and Harris, M. 2011. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J. of Virol. 85:7460-7464.

Chamoun AM, Chockalingam K, Bobardt M, Simeon R, Chang J, Gallay P., Chen Z. 2011. PD 404,182 is a virucidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus. Antimicrobial Agents and Chemotherapy. 56(2):672-681.

Moss SJ, Bobardt M, Leyssen P, Coates N, Chatterji U, Dejian X, Foster T, Liu J, Nur-e-Alam M, Suthar D, Yongsheng C, Warneck T, Neyts J, Gallay P., Wilkinson B, Gregory MA. 2011. Sangamides, a new class of cyclophilin inhibiting host targeted antivirals for treatment of HCV infection. Med. Chem. Commun. 3:944-949.


Waller, H., Chatterji, U., Gallay, P., Parkinson, T., Targett-Adams, P. 2010. The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.  J. Virol. Methods 165:202-210.

Bobardt, M.D., Chatterji, U., Schaffer, L., de Witte, L., and Gallay, P.A., 2010. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrobial Agents and Chemotherapy, 54:2753-2766.

Chatterji, U., Lim, P., Bobardt, M.D., Wieland, S., Cordek, D.G., Vuagniaux, G., Chisari, F., Cameron, C.E., Targett-Adams, P., Parkinson, T., and Gallay, P.A. 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors.  J. Hepatol., 53:50-56.

Chatterji, U., Bobardt, M.D., Lim, P., Gallay, P.A. 2010. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes. J. Gen. Virol. 91:1189-1193.

Fischer, G., Gallay, P.A., Hopkins, S. Cyclophilin inhibitors for the treatment of hepatitis C virus infection. 2010. Curr. Opin. Investig. Drugs, 11:911-918.

Coelmont, L., Chatterji, U., Hanoulle, X., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., Vuagniaux, G., Bartenschlager, R., Gallay, P.A., Lippens, G., and Neyts, J. 2010. Debio 025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A. PLoS One, 5:e13687.


Chatterji, U., Bobardt, M., Selvarajah, S., Yang,F., Tang, H. Sakamoto, N Vuagniaux, G., Parkinson, T., and Gallay, P. 2009. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.  J. Biol. Chem. 284:16998-17005.

Gallay, P.A. 2009. Cyclophilin inhibitors. Clin. Liver Dis. 13:403-417.


Cheng, G., Montero, A., Gastaminza, P., Whitten-Bauer, C., Wieland, S. F., Isogawa, M. Fredericksen, B., Selvarajah, S., Gallay, P., Ghadiri, R., and Chisari, F. V.  2008. A virocidal amphipathic alpha-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. 105:3088-3093.

Bobardt, M., Cheng, G., de Witte, L., Selvarajah, S., Chatterji, U., Beer, B., Geijtenbeek, T. B. H., Chisari, F. V., and Gallay, P. A.  2008. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 105: 5525-5530.

Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., Siwak, A., Cielniak, I., Higersberger, J., Kierkus, J., Aeschlimann, C., Grosgurin, P., Nicolas-Métral, V., Dumont, J.-M., Porchet, H., Crabbé, R., and Scalfaro, P.  2008. The cyclophilin inhibitor Debio 025 shows potent anti-HCV effect in a double-blind, placebo-controlled study in HIV/HCV infected patients.  Hepatology. 47:817-826.

Ptak, R., Gallay, P. A., Jochmans, D., Halestrap, A. P.,  Ruegg, U. T., Pallansch, L. A., Bobardt, M. D., De Bethune, M.-P., Neyts, J., De Clercq,E., Dumont, J.-M., Scalfaro, P., Besseghir, K., Wenger, R. M., and Rosenwirth, B. 2008. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.  Antimicrob. Agents Chemother. 52: 1302-1307.


Bobardt, M.D., Chatterji, U., Selvarajah, S., Van der Schueren B., David, G., Kahn, B. and Gallay, P.A.  2007. Cell-free HIV-1 transcytosis through primary genital epithelial cells. J. Virol. 81:395-405.

de Witte, L., Bobardt, M.D., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T.B.H., and Gallay, P. A.  2007. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1.  Proc. Natl. Acad. Sci. 104: 19464-1949.


Chatterji, U., Bobardt, M.D., Gaskill, P., Sheeter, D., Fox, H. and Gallay P.A. 2006. Trim 5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.  J. Biol. Chem. 281:37025-37033.


de Parseval, A., Bobardt, M.D., Chatterji, A., Chatterji, U., Elder, J.H, David, G., Zolla-Pazner, S., Farzan, M., Lee, T.-H. and Gallay, P.A.   2005. A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs.  J. Biol. Chem. 280:39493-39504.

Chatterji, U., Bobardt, M.D., Stanfield, R., Ptak, R.G., Pallansch, L.A., Ward, P.A., Jones, M.J., Stoddart, C.A., Scalfaro, P., Dumont, J.M., Besseghir, K., Rosenwirth, B. and Gallay, P.A.  2005. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in owl monkey cells.  J. Biol. Chem. 280:40293-40300.


Gallay, P.A.
  2004. Syndecans and HIV-1 pathogenesis.  Microbes and Infection 6:617-622.

Bobardt, M.D., Salmon, P., Wang, L., Esko, J.D., Gabuzda, D., Fiala, M., Trono, D., Van der Schueren, B., David, G. and Gallay, P.A.  2004. Contribution of proteoglycans to HIV-1 brain invasion.  J. Virol. 78:6567-6584.

Bobardt, M.D., Armand-Ugón, M., Clotet, I., Zhang, Z., David, G., Este, J.A. and Gallay, P.A.  2004. Effect of polyanion-resistance on HIV-1 infection.  Virology 325:389-398.


Bobardt, M.D., Saphire, A.C.S., Hung, H-C., Yu, X., Van der Schueren, B., Zhang, Z., David, G. and Gallay, P.A.  2003. Syndecan captures, protects and transmits HIV-1 to T-lymphocytes.  Immunity 18:27-39.